Article Sidebar

Submitted
2 November 2016
Accepted
2 November 2016
Published
2 November 2016
Download
PDF
Statistic
Read Counter : 997 Download : 2073

Main Article Content

Abstract

Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management of ITP is emerged which target is to increase platelet production rate via eltrombopag or romiplostim as the thrombopoietin receptor agonist (TPO-RA). Eltrombopag is given orally while romiplostim is given subcutaneously or intravenously and dose adjustment is depend on platelet count. Both eltrombopag and romiplostim is indicated in minimal response glucocorticoid or intravenous immunoglobulin or splenetomy treatment.

Keywords

Thrombopoietin receptor agonist (TPO-RA) thrombopoietin eltrombopag ITP romiplostim

Article Details

License

Copyright (c) 2016 Jefri Pratama Susanto

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Susanto, J. P. (2016). Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?. Folia Medica Indonesiana, 51(3), 203–207. https://doi.org/10.20473/fmi.v51i3.2840
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Asharianti, A. Sedana, MP. Bintoro, UY. Diansyah, MN. Naskah Lengkap Surabaya Hematologi Onkologi Medik Update-XII (SURABAYA HOM UPDATE-XII) Toward Brighter Management of Hemato Oncology in Asian Region From Bench to Clinical Practice. Fakultas Kedokteran Universitas Airlangga Surabaya- RSUD Dr. Soetomo. 2014: page 16.
  2. Bussel, JB. Kuter, DJ. Pullarkat, V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009; 113:2161-2171)
  3. Cheng, G. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. her Adv Hematol (2012) 3(3) 155–164
  4. Imbach, P. Crowther, M. Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia. N Engl J Med 2011;365:734-41.
  5. Siegal, D. Crowther, M. Cuker, A. Thrombopoietin Receptor Agonists in Primary ITP. Semin Hematol 2013; 50(0 1): S18–S21.
  6. Stasi, R. Rhodes, E. Benjamin, R. Buyck, et al. The Emergence of Thrombopoietin Receptor Agonists as a Novel Treatment for Immune Thrombocytopenia. European Ocology & Haematology 2011;7(1):63-70